Posted by Michael Wonder on 18 Aug 2021
US FDA approves Jardiance (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
18 August 2021 - New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis.
Jardiance (empagliflozin) 10 mg has been approved by the U.S. FDA to reduce the risk of cardiovascular death plus hospitalisation for heart failure in adults with heart failure with reduced ejection fraction, Boehringer Ingelheim and Eli Lilly and Company announced today.
